Stock Track | Hims & Hers Health Soars 5.72% After 35% Plunge Following Novo Nordisk Partnership Termination

Stock Track

06/24

Hims & Hers Health Inc. (HIMS) experienced a volatile trading session on Tuesday, with its stock soaring 5.72% after a dramatic 35% plunge the previous day. The turbulence comes in the wake of Danish ...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1116119736"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116119736\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116119736?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 14:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116119736","market":"sg","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 5.72% After 35% Plunge Following Novo Nordisk Partnership Termination","media":"Stock Track","content":"<div>\n<p>Hims & Hers Health Inc. (HIMS) experienced a volatile trading session on Tuesday, with its stock soaring 5.72% after a dramatic 35% plunge the previous day. The turbulence comes in the wake of Danish ...</p>\n\n<a href=\"\">網頁鏈接</a>\n\n</div>\n","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 5.72% After 35% Plunge Following Novo Nordisk Partnership Termination</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 5.72% After 35% Plunge Following Novo Nordisk Partnership Termination\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-06-24 14:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<div>\n<p>Hims & Hers Health Inc. (HIMS) experienced a volatile trading session on Tuesday, with its stock soaring 5.72% after a dramatic 35% plunge the previous day. The turbulence comes in the wake of Danish ...</p>\n\n<a href=\"\">網頁鏈接</a>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1116119736","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116119736","pubTimestamp":1750747353,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc.  experienced a volatile trading session on Tuesday, with its stock soaring 5.72% after a dramatic 35% plunge the previous day. The turbulence comes in the wake of Danish pharmaceutical giant Novo Nordisk's decision to terminate its collaboration with Hims & Hers for the sale of weight loss drugs, including the popular Wegovy.The partnership, which began in April, ended abruptly due to what Novo Nordisk described as \"deceptive promotion and selling of illegitimate, knockof","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票轨迹Hims&Hers Health在诺和诺德终止合作关系后暴跌35%后飙升5.72%","themeId":"0e4f87550d613fe05f12a314ce8a1e93","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a volatile trading session on Tuesday, with its stock soaring 5.72% after a dramatic 35% plunge the previous day. The turbulence comes in the wake of Danish pharmaceutical giant Novo Nordisk's decision to terminate its collaboration with Hims & Hers for the sale of weight loss drugs, including the popular Wegovy.\nThe partnership, which began in April, ended abruptly due to what Novo Nordisk described as \"deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.\" In response, Hims & Hers CEO Andrew Dudum countered these claims, stating that Novo Nordisk was \"misleading the public\" and had pressured his company to \"control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients.\"\nThe market's reaction to this news was initially severe, with HIMS stock plummeting 35% during Monday's regular trading session. However, the stock showed signs of recovery in after-hours trading on Monday and continued its rebound on Tuesday. This suggests that investors may be reassessing the impact of the partnership dissolution on Hims & Hers' business model. The company's commitment to maintaining a diverse range of treatment options, including compounded medications, could be viewed positively by some market participants.\nAdding to the stock's volatility, Needham downgraded Hims & Hers from Buy to Hold following the Novo Nordisk fallout. Despite these challenges, the stock's resilience on Tuesday indicates that some investors see potential in the company's ability to navigate this setback and continue serving its customer base with a variety of treatment options.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}